COLUMBIA, SC -- (MARKET WIRE) -- 03/18/08 -- Advanced Fertility & Reproductive Endocrinology Institute, LLC today announced it will offer the Repromedix's PlanAhead™ test, an innovative blood test that provides an assessment of a woman's egg supply by combining multiple factors including the measurement of ovary-related hormones AMH, Inhibin B, and FSH. The window of opportunity for a woman to have children by natural conception is dependent upon an adequate supply of eggs which inevitably declines as a woman ages and her "biological clock ticks." PlanAhead enables a woman to compare her estimated egg supply with the normal range expected for women of the same age. In addition, the PlanAhead Report provides valuable directional information about women planning to have children after their late twenties and for those that need to seek further advice from fertility experts to help ensure that they can have their own biological family they were hoping for.

"Advanced Fertility Institute has always incorporated the latest assisted reproductive technologies (ART) into our treatment plans to give our patients the best chance possible of having a baby," said Gail Whitman-Elia, M.D., Medical Director of Advanced Fertility Institute. "We strive to provide our patients with the most advanced testing and treatment options, and PlanAhead will provide women with the individual assessment of their own ovarian reserve to help them make more informed decisions about when to have a child. We're pleased to be in the vanguard of this critical new test."

Repromedix Corp., the PlanAhead test co-developer and leading national diagnostic laboratory for fertility testing, selected Advanced Fertility Institute to be one of a select number of IVF centers to debut the test. Repromedix will expand the PlanAhead launch to major markets across the United States throughout 2008.

PlanAhead is now available to women in the greater Columbia, SC area, and women interested in the PlanAhead test can purchase a test online at www.planaheadtest.com/us or at Advanced Fertility Institute, where they can also have their blood drawn. The blood sample is sent to Repromedix, whose lab performs the advanced testing and submits the report and recommendations to the patient's physician. The cost of the PlanAhead test is $350.

Women interested in learning more about PlanAhead should visit: www.planaheadtest.com/us.

About Advanced Fertility Institute (www.ivfwecare.com)

Advanced Fertility & Reproductive Endocrinology is an award-winning, leading provider of full-service fertility therapy for the Southeast. Under the direction of Gail Whitman-Elia, M.D., FACOG, the practice has established a reputation for consistently high results and top-level, compassionate care.

About Repromedix (www.repromedix.com)

Repromedix is the leading national diagnostic laboratory for fertility testing and offers a multifaceted approach to clinical fertility testing that encompasses many medical disciplines including endocrinology, immunology and genetics. Repromedix offers the most comprehensive suite of advanced diagnostic tests that provide valuable information regarding the complex problems of reproductive failure. Since its inception in 1993, the company has assisted more than 45,000 patients by performing over 100,000 diagnostic tests for recurrent pregnancy loss, premature ovarian failure, male infertility, and unexplained infertility. Repromedix is a portfolio company of Brook Venture Partners, Ironwood Capital Management, and Brooke Private Equity Advisors.

Contact:
Mike Burney
803-238-0300
Email Contact